Advertisement

Anti-Tumour Effects of Platinum Complexes in Experimental Animals

  • T. A. Connors
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 48)

Abstract

The discovery of new types of anti-cancer agent is not always the result of large scale screening or of working hypotheses which suggest that a particular chemical may have anti-tumour properties. Quite frequently new agents are found because of unexpected observations which may be made in fields completely unrelated to cancer chemotherapy.

Keywords

Therapeutic Index Platinum Complex Complete Tumour Regression L1210 Leukemia Plasma Cell Tumour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Clarke, D. A.: Mouse Sarcoma 180. Cancer Res. Suppl. 3, 15 (1955).Google Scholar
  2. 2.
    Cleare, M. J., Hoeschele, J. D.: Anti-tumour platinum compounds. Relationship between structure and activity. Platinum Metals Review 17, 2 (1973).Google Scholar
  3. 3.
    Cleare, M. J., Hoeschele, J. D.: Studies on the anti-tumour activity of Group VIII transition metal complexes. Part I. Platinum(II)complexes. Bio inorganic Chemistry 2, 187 (1973).Google Scholar
  4. 4.
    Cobb, L. M., Mitchley, B. C. V.: Personal communication.Google Scholar
  5. 5.
    Connors, T. A.: Chemotherapy of animal tumours with platinum compounds. In: Advances in anti-microbial and anti-neoplastic chemotherapy, Vol. 2, p. 237. München, Berlin, Wien: Urban Schwarzenberg 1972.Google Scholar
  6. 6.
    Connors, T. A., Jones, M., Ross, W. C. J., Braddock, P. D., Khokhar, A. R., Tobe, M. L.: New platinum complexes with anti-tumour activity. Chem.-Biol. Interactions 5, 415 (1972).Google Scholar
  7. 7.
    Goldin, A.: Rationale of combination chemotherapy based on preclinical experiments. Cancer Chemother. Rep. (part 3 ) 4, 189 (1973).Google Scholar
  8. 8.
    Goldin, A., Mantel, N.: Cancer Chemother. Rep. (in press).Google Scholar
  9. 9.
    Goldin, A., Sandberg, J. S., Henderson, E. S., Newman, J. W.: The chemotherapy of human and animal acute leukaemia. Cancer Chemother. Rep. 55, 309 (1971).Google Scholar
  10. 10.
    Goldin, A., Serpick, A. A., Mantel, N.: Experimental screening procedures and clinical predictability value. Cancer Chemother. Rep. 50, 173 (1966).Google Scholar
  11. 11.
    Harder, H. C., Rosenberg, B.: Inhibitory effects of anti-tumour platinum compounds on DNA, RNA and protein synthesis in mammalian cells in vitro. Int. J. Cancer 6, 207 (1970).PubMedCrossRefGoogle Scholar
  12. 12.
    Howle, J. A., Gale, G. R.: Cis-dichlorodiammine platinum(II) persistent and selective inhibition of DNA synthesis in vivo. Biochem. Pharmacol. 19, 2757 (1970).PubMedCrossRefGoogle Scholar
  13. 13.
    Kociba, R. J., Sleight, S. D.: Acute toxicologic and pathologic effects of cis-diammine dichloroplatinum (NSC-119 875) in the male rat. Cancer Chemother. Rep. (part 1 ) 55, 1 (1971).Google Scholar
  14. 14.
    Kociba, R. J., Sleight, S. D., Rosenberg, B.: Inhibition of dunning ascitic leukaemia and Walker 256 carcinoma with cis-diammine-dichloroplatinum (NSC-119 875). Cancer Chemother. Rep. 54, 325 (1970).Google Scholar
  15. 15.
    Leonard, B. J., Eccleston, E., Jones, D., Todd, P., Walpole, A.: Anti-leukaemic and nephrotoxic properties of platinum compounds. Nature (Lond.) 234, 43 (1971).CrossRefGoogle Scholar
  16. 16.
    Roberts, J. J., Pascoe, J. M.: Cross-linking of complementary strands of DNA in mammalian cells by anti-tumour platinum compounds. Nature (Lond.) 235, 282 (1972).CrossRefGoogle Scholar
  17. 17.
    Rosenberg, B., Van Camp, L., Trosko, J. E., Mansour, V. H.: Platinum compounds: a new class of potent anti-tumour agent. Nature (Lond.) 222, 385 (1969).CrossRefGoogle Scholar
  18. 18.
    Schmidt, L. H., Fradkin, R., Sullivan, R., Flowers, A.: Comparative pharmacology of alkylating agents. Cancer Chemother. Rep. Suppl. 2, pt. I-III (1965).Google Scholar
  19. 19.
    Speer, R. J., Lapis, S., Ridgway, H., Meyers, T. D., Hill, J. M.: Cis platinous diammino dichloride (PDD) in combination therapy of leukaemia L 1210. Advances in anti-microbial and anti-neoplastic chemotherapy. Vol. 2, p. 253. München, Berlin, Wien: Urban Schwarzenberg 1972.Google Scholar
  20. 20.
    Talley, R. W.: Chemotherapy of a mouse reticulum cell sarcoma. Proc. Amer. Ass. Cancer Res. 11, 78 (1970).Google Scholar
  21. 21.
    Van Camp, L., Rosenberg, B.: Combination therapy of cis-dichloro-diammineplatinum(II) with cytoxan against the sarcoma 180 tumor in Swiss white mice. In: Advances in antimicrobial and anti-neoplastic chemotherapy. Vol. 2, p. 239. München, Berlin, Wien: Urban Schwarzenberg 1972.Google Scholar
  22. 22.
    Venditti, J. M., Goldin, A.: Drug synergism in anti-neoplastic chemotherapy. In: Ed. GOLDIN and HAWKING. Advances in Chemotherapy. Vol. 1, p. 397. New York: Academic Press 1964.Google Scholar
  23. 23.
    Welsch, C. W.: Growth inhibition of rat mammary carcinoma induced by cis platinum diamminodichloride(II). J. nat. Cancer. Inst. 47, 1071 (1971).PubMedGoogle Scholar
  24. 24.
    Woodman, R. J., Strica, A. E., Gang, M., Kline, I., Venditti, J. M.: The enhanced therapeutic effect of cis-platinum(II) diamminodichloride against L 1210 leukaemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxo-piperazine-1-yl) propane or several other anti-tumour agents. Chemotherapy 18, 169 (1973).PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1974

Authors and Affiliations

  • T. A. Connors

There are no affiliations available

Personalised recommendations